By Rachel Graf ( August 17, 2017, 7:36 PM EDT) -- An EpiPen direct purchaser's decision to drop a proposed class action, alleging pharmaceutical companies including Mylan Inc. and Pfizer Inc. stifled competition in an effort to drive up prices for their potentially lifesaving allergy treatment, was approved in a New Jersey federal court on Tuesday....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.